1. Home
  2. ACIC vs ERAS Comparison

ACIC vs ERAS Comparison

Compare ACIC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Coastal Insurance Corporation

ACIC

American Coastal Insurance Corporation

N/A

Current Price

$9.77

Market Cap

473.4M

Sector

Finance

ML Signal

N/A

Logo Erasca Inc.

ERAS

Erasca Inc.

N/A

Current Price

$13.60

Market Cap

6.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ACIC
ERAS
Founded
1999
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
473.4M
6.3B
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
ACIC
ERAS
Price
$9.77
$13.60
Analyst Decision
Buy
Buy
Analyst Count
2
10
Target Price
$13.00
★ $25.10
AVG Volume (30 Days)
183.5K
★ 5.1M
Earning Date
10-29-2026
11-12-2026
Dividend Yield
★ 7.64%
N/A
EPS Growth
★ 39.61
36.23
EPS
★ 1.23
N/A
Revenue
★ $335,439,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.98
★ N/A
Revenue Growth
★ 13.07
N/A
52 Week Low
$9.01
$2.81
52 Week High
$13.06
$24.28

Technical Indicators

Market Signals
Indicator
ACIC
ERAS
Relative Strength Index (RSI) 37.07 42.80
Support Level $9.06 $13.18
Resistance Level $11.49 $15.71
Average True Range (ATR) 0.36 1.31
MACD -0.11 -0.13
Stochastic Oscillator 12.59 14.12

Price Performance

Historical Comparison
ACIC
ERAS

About ACIC American Coastal Insurance Corporation

American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: